Medicina (Kaunas, Lithuania), 57 (7), 669
Trending July 27, 2026 2 min read Save Kansas City man potentially cured of HIV SPONSORED CONTENT June 26, 2026 1 min read Save FDA approves Skyrizi for pediatric use in psoriatic disease The FDA approved risankizumab-rzaa for children aged at least 6 years with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy or active psoriatic arthritis, AbbVie announced in a press release
Orlistat is suitable for long-term use in individuals with a BMI of 30 or higher or 27 or higher and weight-related conditions
Consider dose reduction if your resting heart rate consistently exceeds 100 BPM, if you experience persistent palpitations or chest discomfort, or if the heart rate increase significantly affects your exercise tolerance
This is especially the case when you want to lose weight or control diabetes
Puerta, E., Surez-Santiago, J